

ACS

and ENERGY TRANSPORTS

CYTOMAX provides 22 grams of carbohydrates from multiple sources utilizing the body's ability to transport and deliver energy (glucose, fructose and lactate) through unique pathways.¹

Intestine

Muscle

GLUCOSE TRANSPORTER

GLUCOSE

FRUCTOSE TRANSPORTER

FRUCTOSE

HYDROLYZED POLYLACTATE

LACTATE

WATER TRANSPORTER

WATER

The carbohydrate sources in Cytomax utilize the following pathways:

- Maltodextrin and Dextrose follow the Glucose Pathway;
- Crystalline Fructose uses the Fructose Pathway;
- alpha-L-Polylactate¹ relies on the Lactate Pathway;
- Water utilizes the Aquaporin Pathway².

- ✓ **GLUCOSE**
as maltodextrin and dextrose provides
fuel for exercising muscles
- ✓ **FRUCTOSE**
is consumed with glucose increases
of carbohydrate oxidation rates
- ✓ **ALPHA-L-POLYLACTATE**
primary, acid buffering fuel provides
extra energy for muscles

**THE ELECTROLYTES IN CYTOMAX
HELP REPLACE THOSE LOST IN SWEAT***

- ✓ **SODIUM AND POTASSIUM**
Critical for muscle contractions and
supporting fluid balance†
- ✓ **MAGNESIUM**
Necessary for muscle metabolism‡

Strong IPER SERVING: FROM OUR BLEND OF PEPTOR® LEUCINE-ENRICHED WHEY PEPTIDES, L-GLUTAMINE AND L-ALANINE.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

REFERENCES 1. COHEN ET AL. JAMA. 1990; 263: 1025-1030. 2. HANSEN ET AL. INT J EPIDEMIOL. 1991; 20: 103-108. 3. HANSEN ET AL. J EPIDEMIOL COMMUNITY HEALTH. 1992; 46: 103-108. 4. HANSEN ET AL. JAMA. 1993; 269: 1025-1030. 5. HANSEN ET AL. JAMA. 1994; 271: 1025-1030. 6. HANSEN ET AL. JAMA. 1995; 273: 1025-1030. 7. HANSEN ET AL. JAMA. 1996; 275: 1025-1030. 8. HANSEN ET AL. JAMA. 1997; 277: 1025-1030. 9. HANSEN ET AL. JAMA. 1998; 279: 1025-1030. 10. HANSEN ET AL. JAMA. 1999; 281: 1025-1030. 11. HANSEN ET AL. JAMA. 2000; 283: 1025-1030. 12. HANSEN ET AL. JAMA. 2001; 285: 1025-1030. 13. HANSEN ET AL. JAMA. 2002; 287: 1025-1030. 14. HANSEN ET AL. JAMA. 2003; 289: 1025-1030. 15. HANSEN ET AL. JAMA. 2004; 291: 1025-1030. 16. HANSEN ET AL. JAMA. 2005; 293: 1025-1030. 17. HANSEN ET AL. JAMA. 2006; 295: 1025-1030. 18. HANSEN ET AL. JAMA. 2007; 297: 1025-1030. 19. HANSEN ET AL. JAMA. 2008; 299: 1025-1030. 20. HANSEN ET AL. JAMA. 2009; 301: 1025-1030. 21. HANSEN ET AL. JAMA. 2010; 303: 1025-1030. 22. HANSEN ET AL. JAMA. 2011; 305: 1025-1030. 23. HANSEN ET AL. JAMA. 2012; 307: 1025-1030. 24. HANSEN ET AL. JAMA. 2013; 309: 1025-1030. 25. HANSEN ET AL. JAMA. 2014; 311: 1025-1030. 26. HANSEN ET AL. JAMA. 2015; 313: 1025-1030. 27. HANSEN ET AL. JAMA. 2016; 315: 1025-1030. 28. HANSEN ET AL. JAMA. 2017; 317: 1025-1030. 29. HANSEN ET AL. JAMA. 2018; 319: 1025-1030. 30. HANSEN ET AL. JAMA. 2019; 321: 1025-1030. 31. HANSEN ET AL. JAMA. 2020; 323: 1025-1030. 32. HANSEN ET AL. JAMA. 2021; 325: 1025-1030. 33. HANSEN ET AL. JAMA. 2022; 327: 1025-1030. 34. HANSEN ET AL. JAMA. 2023; 329: 1025-1030. 35. HANSEN ET AL. JAMA. 2024; 331: 1025-1030. 36. HANSEN ET AL. JAMA. 2025; 333: 1025-1030. 37. HANSEN ET AL. JAMA. 2026; 335: 1025-1030. 38. HANSEN ET AL. JAMA. 2027; 337: 1025-1030. 39. HANSEN ET AL. JAMA. 2028; 339: 1025-1030. 40. HANSEN ET AL. JAMA. 2029; 341: 1025-1030. 41. HANSEN ET AL. JAMA. 2030; 343: 1025-1030. 42. HANSEN ET AL. JAMA. 2031; 345: 1025-1030. 43. HANSEN ET AL. JAMA. 2032; 347: 1025-1030. 44. HANSEN ET AL. JAMA. 2033; 349: 1025-1030. 45. HANSEN ET AL. JAMA. 2034; 351: 1025-1030. 46. HANSEN ET AL. JAMA. 2035; 353: 1025-1030. 47. HANSEN ET AL. JAMA. 2036; 355: 1025-1030. 48. HANSEN ET AL. JAMA. 2037; 357: 1025-1030. 49. HANSEN ET AL. JAMA. 2038; 359: 1025-1030. 50. HANSEN ET AL. JAMA. 2039; 361: 1025-1030. 51. HANSEN ET AL. JAMA. 2040; 363: 1025-1030. 52. HANSEN ET AL. JAMA. 2041; 365: 1025-1030. 53. HANSEN ET AL. JAMA. 2042; 367: 1025-1030. 54. HANSEN ET AL. JAMA. 2043; 369: 1025-1030. 55. HANSEN ET AL. JAMA. 2044; 371: 1025-1030. 56. HANSEN ET AL. JAMA. 2045; 373: 1025-1030. 57. HANSEN ET AL. JAMA. 2046; 375: 1025-1030. 58. HANSEN ET AL. JAMA. 2047; 377: 1025-1030. 59. HANSEN ET AL. JAMA. 2048; 379: 1025-1030. 60. HANSEN ET AL. JAMA. 2049; 381: 1025-1030. 61. HANSEN ET AL. JAMA. 2050; 383: 1025-1030. 62. HANSEN ET AL. JAMA. 2051; 385: 1025-1030. 63. HANSEN ET AL. JAMA. 2052; 387: 1025-1030. 64. HANSEN ET AL. JAMA. 2053; 389: 1025-1030. 65. HANSEN ET AL. JAMA. 2054; 391: 1025-1030. 66. HANSEN ET AL. JAMA. 2055; 393: 1025-1030. 67. HANSEN ET AL. JAMA. 2056; 395: 1025-1030. 68. HANSEN ET AL. JAMA. 2057; 397: 1025-1030. 69. HANSEN ET AL. JAMA. 2058; 399: 1025-1030. 70. HANSEN ET AL. JAMA. 2059; 401: 1025-1030. 71. HANSEN ET AL. JAMA. 2060; 403: 1025-1030. 72. HANSEN ET AL. JAMA. 2061; 405: 1025-1030. 73. HANSEN ET AL. JAMA. 2062; 407: 1025-1030. 74. HANSEN ET AL. JAMA. 2063; 409: 1025-1030. 75. HANSEN ET AL. JAMA. 2064; 411: 1025-1030. 76. HANSEN ET AL. JAMA. 2065; 413: 1025-1030. 77. HANSEN ET AL. JAMA. 2066; 415: 1025-1030. 78. HANSEN ET AL. JAMA. 2067; 417: 1025-1030. 79. HANSEN ET AL. JAMA. 2068; 419: 1025-1030. 80. HANSEN ET AL. JAMA. 2069; 421: 1025-1030. 81. HANSEN ET AL. JAMA. 2070; 423: 1025-1030. 82. HANSEN ET AL. JAMA. 2071; 425: 1025-1030. 83. HANSEN ET AL. JAMA. 2072; 427: 1025-1030. 84. HANSEN ET AL. JAMA. 2073; 429: 1025-1030. 85. HANSEN ET AL. JAMA. 2074; 431: 1025-1030. 86. HANSEN ET AL. JAMA. 2075; 433: 1025-1030. 87. HANSEN ET AL. JAMA. 2076; 435: 1025-1030. 88. HANSEN ET AL. JAMA. 2077; 437: 1025-1030. 89. HANSEN ET AL. JAMA. 2078; 439: 1025-1030. 90. HANSEN ET AL. JAMA. 2079; 441: 1025-1030. 91. HANSEN ET AL. JAMA. 2080; 443: 1025-1030. 92. HANSEN ET AL. JAMA. 2081; 445: 1025-1030. 93. HANSEN ET AL. JAMA. 2082; 447: 1025-1030. 94. HANSEN ET AL. JAMA. 2083; 449: 1025-1030. 95. HANSEN ET AL. JAMA. 2084; 451: 1025-1030. 96. HANSEN ET AL. JAMA. 2085; 453: 1025-1030. 97. HANSEN ET AL. JAMA. 2086; 455: 1025-1030. 98. HANSEN ET AL. JAMA. 2087; 457: 1025-1030. 99. HANSEN ET AL. JAMA. 2088; 459: 1025-1030. 100. HANSEN ET AL. JAMA. 2089; 461: 1025-1030. 101. HANSEN ET AL. JAMA. 2090; 463: 1025-1030. 102. HANSEN ET AL. JAMA. 2091; 465: 1025-1030. 103. HANSEN ET AL. JAMA. 2092; 467: 1025-1030. 104. HANSEN ET AL. JAMA. 2093; 469: 1025-1030. 105. HANSEN ET AL. JAMA. 2094; 471: 1025-1030. 106. HANSEN ET AL. JAMA. 2095; 473: 1025-1030. 107. HANSEN ET AL. JAMA. 2096; 475: 1025-1030. 108. HANSEN ET AL. JAMA. 2097; 477: 1025-1030. 109. HANSEN ET AL. JAMA. 2098; 479: 1025-1030. 110. HANSEN ET AL. JAMA. 2099; 481: 1025-1030. 111. HANSEN ET AL. JAMA. 2100; 483: 1025-1030. 112. HANSEN ET AL. JAMA. 2101; 485: 1025-1030. 113. HANSEN ET AL. JAMA. 2102; 487: 1025-1030. 114. HANSEN ET AL. JAMA. 2103; 489: 1025-1030. 115. HANSEN ET AL. JAMA. 2104; 491: 1025-1030. 116. HANSEN ET AL. JAMA. 2105; 493: 1025-1030. 117. HANSEN ET AL. JAMA. 21



STEVIA

NET WT 24 OZ (1.5 LBS/680g)

BUILDING ATHLETES FROM THE INSIDE OUT™

СУТОМАХ®

SPORTS PERFORMANCE MIX

POST-GRADUATE STUDIES

POMEGRANATE BERRY

1979 03 27 000000 000000

ESSENTIAL ELECTROLYTES

**RAPID &
SUSTAINED
ENERGY**

IMPROVES ENDURANCE

FREE
OF
BANNED
SUBSTANCES



Copyright © 2007
 Pearson Education, Inc.

Supplement Facts

Serving Size 8 1/2 cups (20g) Servings 1 container
Calories Per Container approx. 27

	Amount Per Serving	%DV*
Calories	90	
Total Carbohydrate	22g	7%
Sugars	12g	
Protein	~1g	
Vitamin C (as ascorbic acid)	60mg	100%
Calcium (as calcium phosphate, calcium succinate)	6mg	6%
Magnesium (as magnesium oxide, magnesium succinate)	14mg	4%
Chromium (as chromium chloride)	60mcg	40%
Sodium (as sodium citrate)	120mg	6%
Potassium (as potassium citrate, monopotassium phosphate, potassium succinate)	60mg	2%

Advanced Technology Systems
constructs and maintains nuclear
power plant structures

Ammonia Acid Phosphate (MAP)
 100% water-soluble, 18-46-0
 100% water-soluble, 18-46-0

[illegible]

FOR INFORMATION
ON CYTOSPORT PRODUCTS
OR TO REPORT ADVERSE EFFECTS
CALL 1-800-790-4479 OR EMAIL
PRODUCTS@CYTOSPORT.COM
CYTOSPORT DENVER, CO 80501
CYTOMAX.COM
(303)CYTOSPORT, INC.

GLUTEN FREE

[illegible]

CONTAINS INGREDIENTS DERIVED FROM MILK AND SOY.
THIS PRODUCT IS MANUFACTURED IN A FACILITY THAT PROCESSES
MILK AND SOY. PLEASE SEE US AT 1000.

TABLE 1. *Continued*

FUEL ESSENTIAL ELECTROLYTES

CARBS	SODIUM	POTASSIUM	CALCIUM	IRON
22g	120mg	60mg	6mg	14mg

DIRECTIONS and USE



Begin drinking CytoMax 15 minutes prior to exercise. Continue drinking throughout exercise, consume 80-120 fl.oz. every 30 minutes, or as needed.



"Our graduates are trained to actively promote sustainable development, in compliance with the ISO International Certificate for the program, which includes an intense faculty training, every time up to 100% ISO compliance. Sustainable America A Ltd. have subsidiaries exist in our field."

11233-1074-0117

